Opioid-sparing utility of subcutaneous analgesia systems in pediatric oncology patients following major tumor resection surgery: A matched case-control study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: For pediatric oncology patients undergoing major tumor surgery, subcutaneous analgesic systems (SAS) have been suggested as a potential pain-relief alternative to epidural analgesia. Studies randomizing the two modalities have not demonstrated benefit of SAS but suffer from inherent bias due to frequent contraindications to epidural analgesia in this population. We sought to quantify the incremental analgesic benefit of SAS versus standard intravenous analgesia following major pediatric oncology surgeries, adjusting for potentially confounding factors. METHODS: We performed a retrospective case-control study, with subjects matched for age group and surgical site, and powered it to detect an equivalent rate of additional postoperative morphine use in controls versus patients with SAS use as compared to respective controls compared to patients who had epidural analgesia. RESULTS: Eighteen patients received standard perioperative analgesia and SAS following abdominal or thoracic tumor resection, while 18 age- and surgical site-matched controls received only standard analgesia without SAS or epidural. SAS pumps were utilized for average 2.89 days, with no adverse outcomes or toxicity-related complications. Equivalent postoperative opioid use was lower in the SAS group, particularly on postoperative day 2 (P = 0.035); postoperative pain scores and clinical recovery duration were equivalent in both groups. CONCLUSION: In pediatric oncology patients undergoing major surgical resections, SAS offers a feasible, safe and opioid-sparing analgesic option during their early postoperative recovery. In these patients, SAS may offer incremental postoperative pain relief over standard analgesia, while avoiding the potential risks of invasive neuraxial blockade.